3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
about
Molecular imaging: 18F-FDG PET and a whole lot more.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma(18)F-FLT PET/CT imaging in a Wister rabbit inflammation model.Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCLSpecific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.Limits of [18F]-FLT PET as a biomarker of proliferation in oncologyThe role of DNA synthesis imaging in cancer in the era of targeted therapeuticsAssessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapyPET in lymphoma.Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors.The Positron Emission Tomography Tracer 3'-Deoxy-3'-[18F]Fluorothymidine ([18F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia enterocolitica Infection in Mice[18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.Advances in PET Detection of the Antitumor T Cell Response.18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer.
P2860
Q30482989-F7C200F9-EA31-4FDF-8C87-24FCD2601180Q33706877-026473E4-ECEE-493D-B799-A1507CD72325Q33769525-D64EEBE4-959E-4988-AEB1-A3493C4C8494Q33924541-A2F53678-C529-4271-A470-5D8F17389A03Q34100855-CE01D10C-9F8A-4BC0-B264-2273374B5441Q34203953-861D651D-7398-45A7-A5B0-F42626380D35Q34557875-08094BB0-250F-40EA-9335-3A32C1E9FD2DQ34648592-7D6209E1-D7B8-400A-B661-9E8150FDBE4AQ34907192-FF2CFA93-F092-4424-B03E-39CCDF3FF4AEQ35031831-9F424BB5-209B-4193-8B2F-77FB781D61E2Q35554535-78B1020C-8AE2-4E9D-B2D0-4A2E9DD11442Q35650641-DD5372F9-38C9-44A5-BF6E-C92F9592B168Q35661959-883837C9-5CE4-4921-81EE-EB2E685417FBQ36152809-B18EE71A-728D-4464-B27C-E5770DBBB278Q36528174-F9F61BBE-3450-4DEB-B4BE-1A1F746D58D4Q36533822-EB74DF88-AA33-49D2-A33F-ADBF16114F83Q36816955-3CC826A6-C6F0-475E-AFB9-1F1E3F9BF086Q37077354-F4CC708C-6245-4D74-A536-B47CE75A6CD1Q37285365-794E1067-3319-4719-B1BF-AFA78B581FEBQ37341585-63856E82-59DD-4913-A899-49FB7334930CQ37618076-9B42931D-D9DB-4604-9ECC-0F0E36315B37Q37825149-4698AA39-793D-4128-A9F8-0D96F9BD3D97Q38846891-0D4CCEFB-F576-42AF-AE14-83F3A5333F34Q54988307-A75E6E55-FC7F-4C81-B583-3EB0F6FF34DF
P2860
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@ast
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@en
3'-[18F]fluoro-3'-deoxythymidine
@nl
type
label
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@ast
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@en
3'-[18F]fluoro-3'-deoxythymidine
@nl
prefLabel
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@ast
3'-[18F]fluoro-3'-deoxythymidi ...... odel and in the human disease.
@en
3'-[18F]fluoro-3'-deoxythymidine
@nl
P2093
P1433
P1476
3'-[18F]fluoro-3'-deoxythymidi ...... model and in the human disease
@en
P2093
Andreas Buck
Bernd Neumaier
Edgar Wawra
Frank Leithäuser
Gerd Munzert
Markus Bangerter
Martin Bommer
Martin Wagner
Stefan Schultheiss
Sven N Reske
P304
P407
P577
2003-05-01T00:00:00Z